|Title||Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.|
|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Puca L, Vlachostergios PJ, Beltran H|
|Journal||Cold Spring Harb Perspect Med|
|Date Published||2018 May 29|
Although a de novo clinical presentation of small cell neuroendocrine carcinoma of the prostate is rare, a subset of patients previously diagnosed with prostate adenocarcinoma may develop neuroendocrine features in later stages of castration-resistant prostate cancer (CRPC) progression as a result of treatment resistance. Despite sharing clinical, histologic, and some molecular features with other neuroendocrine carcinomas, including small cell lung cancer, castration-resistant neuroendocrine prostate cancer (CRPC-NE) is clonally derived from prostate adenocarcinoma. CRPC-NE therefore retains early prostate cancer genomic alterations and acquires new molecular changes making them resistant to traditional CRPC therapies. This review focuses on recent advances in our understanding of CRPC-NE biology, the transdifferentiation/plasticity process, and development and characterization of relevant CRPC-NE preclinical models.
|Alternate Journal||Cold Spring Harb Perspect Med|